Table 1.
Characteristic | Direct-to-Implant Reconstruction (n = 21) | Two-Stage Breast Reconstruction (n = 26) | Total (n = 47) |
---|---|---|---|
Age, years (mean ± SD) | 55.24 ± 8 | 56.12 ± 7.06 | 55.7 ± 7.42 |
Body mass index, kg/m2 (mean ± SD) | 24.66 ± 1.4 | 24.8 ± 1.8 | 24.73 ± 1.62 |
Comorbidities, n (%) | |||
- Hypertension | 10 (47.6) | 8 (30.8) | 18 (38.3) |
- Diabetes mellitus | 5 (23.8) | 9 (34.6) | 14 (25.53) |
- Hyperlipidemia | 2 (9.52) | 2 (7.7) | 4 (8.51) |
Preoperative implant size, cc (mean ± SD) | 364.5 ± 56.1 | 365.4 ± 54.05 | 365 ± 54.37 |
Mastectomy type, n (%) | |||
- NSM | 14 (66.7) | 14 (56.85) | 28 (59.57) |
- SSM | 7 (33.3) | 12 (46.15) | 19 (40.43) |
Mastectomy specimen weight, g (mean ± SD) | 271.43 ± 61.07 | 316.96 ± 70.66 | 296.62 ± 69.7 |
Tissue expander size, cc (mean ± SD) | N/A | 311.54 ± 63.73 | N/A |
Fills required to reach final implant size (mean ± SD) | N/A | 4 ± 1.3 | N/A |
Final implant volume, cc (mean ± SD) | 314.05 ± 30.52 | 361.92 ± 83 | 340.53 ± 68.73 |
Access Type for Augmentation, n (%) | |||
- Inframammary fold | 8 (38.1) | 10 (38.5) | 18 (38.3) |
- Periareolar | 7 (33.3) | 9 (34.6) | 16 (34.0) |
- Inverted-T | 6 (28.6) | 7 (26.9) | 13 (27.7) |
Adjuvant/Neoadjuvant Therapies, n (%) | |||
- Neoadjuvant chemotherapy | 5 (23.8) | 6 (23.1) | 11 (23.4) |
- Adjuvant chemotherapy | 3 (14.3) | 4 (15.4) | 7 (14.9) |
- Radiotherapy | 7 (33.3) | 8 (30.8) | 15 (31.9) |
Note: Values are expressed as mean ± standard deviation, median (range), or n (%). NSM: nipple-sparing mastectomy; SSM: skin-sparing mastectomy.